https://doi.org/10.4081/mem.2004.638
International experimentations. The debate on placebo-controlled studies
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The starting point of the present work is an article by P. Lurie and S.M. Wolfe published in the New England Journal of Medicine in 1997. In this article the authors showed some trials on short regimen of AZT in perinatal transmission of Hiv that they accuse of being unethical. These studies were sponsored by western organizations and carried out in some sub-Saharian African and Asian countries. The most important ethical question pointed out was the use of a placebo-controlled arm even if the Zidovudine were already used as standard therapy for the reduction of the perinatal transmission of HIV, after a randomized controlled trials performed in Usa and France that proved its effectiveness.
In the first part of the article international literature in the five-years period before and after the publication by Lurie and Wolfe is analyzed. A statistically significant increment in publications on ethics of clinical research in developing countries in the last period is shown.
In the second part of the work the subject of ethical justification of the placebo-controlled arm use in developing countries when a standard therapy is known is analyzed. Pros and cons are explained basing our analysis especially on interpretative categories by A.J. London.
The conclusions suggest that this clinical trial design, in such conditions, is not ethically and logically sound. Nevertheless the rightfulness of the trial results transferability between populations with different historical and cultural identities is yet under discussion.
How to Cite
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
An Open Access Publication is one that meets the following two conditions:
- the author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.
- a complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.